1. Home
  2. DCBO vs BWAY Comparison

DCBO vs BWAY Comparison

Compare DCBO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

HOLD

Current Price

$24.85

Market Cap

584.3M

Sector

N/A

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$14.18

Market Cap

578.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCBO
BWAY
Founded
2016
2003
Country
Canada
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
584.3M
578.5M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
DCBO
BWAY
Price
$24.85
$14.18
Analyst Decision
Buy
Strong Buy
Analyst Count
9
2
Target Price
$32.00
$13.25
AVG Volume (30 Days)
71.0K
108.7K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.89
$309.69
Revenue Next Year
$11.44
$26.21
P/E Ratio
$22.04
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$14.39
$11.77
52 Week High
$30.80
$26.63

Technical Indicators

Market Signals
Indicator
DCBO
BWAY
Relative Strength Index (RSI) 65.48 44.67
Support Level $16.37 $14.08
Resistance Level N/A $14.85
Average True Range (ATR) 0.78 0.53
MACD 0.03 -0.06
Stochastic Oscillator 74.89 19.25

Price Performance

Historical Comparison
DCBO
BWAY

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: